Answer
Synagis (palivizumab) is contraindicated in people with hypersensitivity to palivizumab, any of its excipients, or other humanised monoclonal antibodies.
Sources for this answer
- Synagis 50 mg/0.5 ml solution for injectionAstraZeneca UK Limited · emc · SmPC §4.3 Contraindications · Version 5Document updated
Sources checked